MYC and neoplasm: Studies have revealed genetic heterogeneity between primary tumors and BrM, [25, 28–31], with BrM from lung adenocarcinoma showing higher amplification rates of MYC, YAP1, and MMP13, alongside deletions in CDKN2A/B, compared to the primary tumor [32].